Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2021

View Archived Issues

AAV-TNALP-D10 shows potential as one-time-dose treatment in murine model of hypophosphatasia

Cold exposure ameliorates active experimental autoimmune encephalomyelitis

Takinib inhibits STAT3 activation and shows promise for treating rheumatoid arthritis

IL-40 is upregulated in rheumatoid arthritis and decreases following depletion therapy

Targeting NNMT as novel therapeutic strategy for fibrotic diseases

Sumitomo Dainippon Pharma patents new compounds for epilepsy

Roche discloses GABA-A receptor PAMs

Taiho Pharmaceutical presents new GTPase KRAS mutant inhibitors

Plexxikon identifies new CD73 inhibitors

C4X Discovery Holdings patents NFE2L2 activators

BioArctic developing antibody treatments targeting TDP-43 for ALS

Enhancing endothelial cell S1PR1 signaling attenuates arthritis in vivo

CPI-381: a first-in-class TREX1 inhibitor with antitumor activity in preclinical models

BAY-56-6544 improves vasomotor function in accelerated-aging model

Rat model mimics the features of cerebral small vessel disease

Soluble ACE2 decoy peptide ameliorates SARS-CoV-2 lung vascular injury

AASLD meeting: Cholangiocytes can induce liver regeneration

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...